Azathioprine therapy for steroid-resistant Henoch-Schönlein purpura: a report of 6 cases
| Autor: | Peri H. Pepmueller, Paul V. Tuttle, Lampros Fotis, Kevin W. Baszis, Terry L. Moore, Andrew J. White |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Henoch-Schonlein purpura IgA Vasculitis Case Report Azathioprine Methylprednisolone 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Rheumatology Refractory Recurrence immune system diseases Prednisone 030225 pediatrics Internal medicine medicine Humans Immunology and Allergy Treatment Failure Pediatrics Perinatology and Child Health Child Glucocorticoids Purpura Schoenlein-Henoch business.industry medicine.disease Dermatology Purpura Treatment Outcome Pediatrics Perinatology and Child Health Immunology Steroids Female medicine.symptom business Nephritis Immunosuppressive Agents medicine.drug |
| Zdroj: | Pediatric Rheumatology Online Journal |
| ISSN: | 1546-0096 |
| DOI: | 10.1186/s12969-016-0100-x |
| Popis: | Background A small percentage of children with Henoch-Schönlein purpura (HSP) develop a chronic form of the disease that often requires prolonged corticosteroid therapy. Disease modifying anti-rheumatic agents (DMARDs) or biologics have been successfully used to treat those refractory cases. Azathioprine is a DMARD that has been reported to be effective in HSP nephritis and in adult cutaneous leukocytoclastic vasculitis, a condition with cutaneous histology similar to HSP. Case presentation A description of 6 cases with relapsing HSP without significant renal involvement, treated with azathioprine are reported. All 6 cases met the classification criteria for the diagnosis of HSP, had relapsing symptoms despite corticosteroid use, were successfully treated with azathioprine and were tapered off of corticosteroids. The duration of azathioprine therapy ranged from 7–21 months and no adverse events were reported. Conclusions Azathioprine is effective in controlling prolonged relapsing symptoms of HSP, allowing earlier discontinuation of corticosteroids. This report shows that azathioprine can be included in the therapeutic options for relapsing HSP and is the first case series in the literature of azathioprine use in HSP without significant renal involvement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|